Literature DB >> 1861630

Growth hormone alters lipolysis and hormone-sensitive lipase activity in 3T3-F442A adipocytes.

J Dietz1, J Schwartz.   

Abstract

While growth hormone (GH) has long been known as a lipolytic hormone, it has been difficult to study the cellular mechanisms for this effect. Since cultured 3T3-F442A adipocytes have recently proven to be useful to study chronic effects of GH on adipocyte metabolism, we examined the effects of GH on lipolysis. In these cells, GH alone produced a dose-dependent increase in the release of glycerol after 24 to 48 hours. The maximum increase occurred with 10 ng/mL human GH. The effect of GH was similar in the presence and absence of dexamethasone. Under each condition, the stimulation of glycerol release was accompanied by a GH-induced increase in the activity of hormone-sensitive lipase (HSL), a key lipolytic enzyme. The increase in HSL required 24 hours with GH and lasted at least 48 hours. The increase in HSL activity by epinephrine, like glycerol release, was potentiated by GH. Although GH potently simulates the activity of the lipogenic enzyme glycerol phosphate dehydrogenase (GPD) in differentiating 3T3-F442A preadipocytes, GH had a negligible effect on GPD activity in the differentiated adipocytes with chronic or short-term incubation. However, in contrast to the chronic effect of GH, short-term (30-minute) incubation with GH inhibited epinephrine-stimulated glycerol release, a characteristic transient antilipolytic effect of GH. These studies indicate that chronic GH treatment is lipolytic in cultured 3T3-F442A adipocytes, and document that lipolytic responses to GH involve an increase in the activity of HSL.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1861630     DOI: 10.1016/0026-0495(91)90006-i

Source DB:  PubMed          Journal:  Metabolism        ISSN: 0026-0495            Impact factor:   8.694


  18 in total

1.  Growth hormone controls lipolysis by regulation of FSP27 expression.

Authors:  Rita Sharma; Quyen Luong; Vishva M Sharma; Mitchell Harberson; Brian Harper; Andrew Colborn; Darlene E Berryman; Niels Jessen; Jens Otto Lunde Jørgensen; John J Kopchick; Vishwajeet Puri; Kevin Y Lee
Journal:  J Endocrinol       Date:  2018-12-01       Impact factor: 4.286

Review 2.  Pediatric obesity: etiology and treatment.

Authors:  Melissa K Crocker; Jack A Yanovski
Journal:  Pediatr Clin North Am       Date:  2011-10       Impact factor: 3.278

Review 3.  A model for tissue-specific inducible insulin-like growth factor-I (IGF-I) inactivation to determine the physiological role of liver-derived IGF-I.

Authors:  Klara Sjögren; John-Olov Jansson; Olle G P Isaksson; Claes Ohlsson
Journal:  Endocrine       Date:  2002-12       Impact factor: 3.633

4.  Growth hormone receptor expression in human gluteal versus abdominal subcutaneous adipose tissue: Association with body shape.

Authors:  Susan K Fried; Karen K Miller; Kalypso Karastergiou; Miriam A Bredella; Mi-Jeong Lee; Steven R Smith
Journal:  Obesity (Silver Spring)       Date:  2016-03-26       Impact factor: 5.002

5.  Insulin-like growth factor-I in man enhances lipid mobilization and oxidation induced by a growth hormone pulse.

Authors:  T L Bianda; M A Hussain; A Keller; Y Glatz; O Schmitz; J S Christiansen; K G Alberti; E R Froesch
Journal:  Diabetologia       Date:  1996-08       Impact factor: 10.122

Review 6.  Pediatric obesity: etiology and treatment.

Authors:  Melissa K Crocker; Jack A Yanovski
Journal:  Endocrinol Metab Clin North Am       Date:  2009-09       Impact factor: 4.741

7.  Comparison of the effects of growth hormone and insulin-like growth factor I on substrate oxidation and on insulin sensitivity in growth hormone-deficient humans.

Authors:  M A Hussain; O Schmitz; A Mengel; Y Glatz; J S Christiansen; J Zapf; E R Froesch
Journal:  J Clin Invest       Date:  1994-09       Impact factor: 14.808

8.  Increased hepatic delta 6-desaturase activity with growth hormone expression in the MG101 transgenic mouse.

Authors:  M T Nakamura; S D Phinney; A B Tang; A M Oberbauer; J B German; J D Murray
Journal:  Lipids       Date:  1996-02       Impact factor: 1.880

9.  Growth hormone deficiency by growth hormone releasing hormone-arginine testing criteria predicts increased cardiovascular risk markers in normal young overweight and obese women.

Authors:  Andrea L Utz; Ami Yamamoto; Linda Hemphill; Karen K Miller
Journal:  J Clin Endocrinol Metab       Date:  2008-04-29       Impact factor: 5.958

10.  JAK2, but not Src family kinases, is required for STAT, ERK, and Akt signaling in response to growth hormone in preadipocytes and hepatoma cells.

Authors:  Hui Jin; Nathan J Lanning; Christin Carter-Su
Journal:  Mol Endocrinol       Date:  2008-05-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.